Androgen signaling in prostate cancer

Charles Dai, Hannelore Heemers, Nima Sharifi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.

Original languageEnglish (US)
Article numbera030452
JournalCold Spring Harbor perspectives in medicine
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Androgens
Prostatic Neoplasms
Castration
Androgen Receptors
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Androgen signaling in prostate cancer. / Dai, Charles; Heemers, Hannelore; Sharifi, Nima.

In: Cold Spring Harbor perspectives in medicine, Vol. 7, No. 9, a030452, 01.09.2017.

Research output: Contribution to journalArticle

Dai, Charles ; Heemers, Hannelore ; Sharifi, Nima. / Androgen signaling in prostate cancer. In: Cold Spring Harbor perspectives in medicine. 2017 ; Vol. 7, No. 9.
@article{17a70b7b69be46deb14db3adfad0af91,
title = "Androgen signaling in prostate cancer",
abstract = "The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.",
author = "Charles Dai and Hannelore Heemers and Nima Sharifi",
year = "2017",
month = "9",
day = "1",
doi = "10.1101/cshperspect.a030452",
language = "English (US)",
volume = "7",
journal = "Cold Spring Harbor perspectives in medicine",
issn = "2157-1422",
publisher = "Cold Spring Harbor Laboratory Press",
number = "9",

}

TY - JOUR

T1 - Androgen signaling in prostate cancer

AU - Dai, Charles

AU - Heemers, Hannelore

AU - Sharifi, Nima

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.

AB - The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85025088881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025088881&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a030452

DO - 10.1101/cshperspect.a030452

M3 - Article

C2 - 28389515

AN - SCOPUS:85025088881

VL - 7

JO - Cold Spring Harbor perspectives in medicine

JF - Cold Spring Harbor perspectives in medicine

SN - 2157-1422

IS - 9

M1 - a030452

ER -